{"id":"W2761396813","doi":"10.1200/jco.2017.35.15_suppl.tps4136","title":"Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC)—An international study organized by the Australasian Gastrointestinal Trials Group (AGITG).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Regorafenib; Internal medicine; Clinical endpoint; Placebo; Ramucirumab; Hazard ratio; Bevacizumab; Population; Oncology; Adverse effect; Refractory (planetary science); Surrogate endpoint; Phases of clinical research; Cancer; Clinical trial; Chemotherapy; Colorectal cancer; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0187152,0.0003778221,0.004787498,0.0003647641,0.0002043146,0.00008230128,0.001160835,0.0001685885,0.0006387728],"category_scores_gemma":[0.01298615,0.0002181982,0.0007627544,0.0001730645,0.0003098092,0.0005475771,0.0002160595,0.001780979,0.000002119556],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000352799,"about_ca_system_score_gemma":0.001029875,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004317224,"about_ca_topic_score_gemma":0.00180645,"domain_scores_codex":[0.9897764,0.002226282,0.006175741,0.000462232,0.0009464836,0.0004127992],"domain_scores_gemma":[0.985462,0.003166932,0.009536291,0.0007022051,0.0007487774,0.0003838619],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7387837,0.02168461,0.2113493,0.00001141228,0.001551001,0.0007754219,0.0006643261,0.00004473086,0.0005424605,0.000007137181,0.0007720512,0.02381392],"study_design_scores_gemma":[0.8145141,0.05445277,0.1221823,0.0001237984,0.001644166,0.00007798822,0.005589887,0.000127922,0.00002295773,0.00001215329,0.001129849,0.0001220627],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9885266,0.00007268163,0.00009826932,0.003879683,0.002077379,0.004810086,0.0000118421,0.00001306266,0.0005104411],"genre_scores_gemma":[0.9961194,0.0001237924,0.0005774882,0.0002146474,0.001345032,0.000130951,0.000007921425,0.0000335375,0.001447164],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08916695,"threshold_uncertainty_score":0.9953279,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1891700578129553,"score_gpt":0.5260266435446584,"score_spread":0.3368565857317031,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}